Literature DB >> 15580617

Preferences for different methods of communicating information regarding adjuvant chemotherapy for breast cancer.

Jamie L Studts1, Troy D Abell, Lynne M Roetzer, Ashley N Albers, Kelly M McMasters, Celia Chao.   

Abstract

Many patients play an active role in determining their cancer treatments, and the communication of medical information influences patient decision-making. This study examined participants' preferences between various methods of communicating quantitative risks and benefits of adjuvant chemotherapy. Using clinical vignettes, participants were first asked to decide whether or not to endorse chemotherapy and were subsequently asked about their preferences for the methods used to communicate the risks and benefits. Participants preferred the absolute survival benefit method over negatively framed methods, such as relative or absolute risk reduction. We also present analysis of qualitative data which supports the conclusions drawn from quantitative analyses. In summary, the absolute survival benefit was shown to be the superior method of communicating quantitative risks and benefits of chemotherapy. Failure to use clear and concise methods of communicating quantitative risk and benefit information may compromise efforts to obtain informed consent for treatment. Copyright (c) 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15580617     DOI: 10.1002/pon.886

Source DB:  PubMed          Journal:  Psychooncology        ISSN: 1057-9249            Impact factor:   3.894


  4 in total

1.  Breast cancer patients' treatment expectations after exposure to the decision aid program adjuvant online: the influence of numeracy.

Authors:  Isaac M Lipkus; Ellen Peters; Gretchen Kimmick; Vlayka Liotcheva; Paul Marcom
Journal:  Med Decis Making       Date:  2010-02-16       Impact factor: 2.583

2.  Association of Breast Cancer Knowledge With Receipt of Guideline-Recommended Breast Cancer Treatment.

Authors:  Rachel A Freedman; Elena M Kouri; Dee W West; Joyce Lii; Nancy L Keating
Journal:  J Oncol Pract       Date:  2016-05-10       Impact factor: 3.714

3.  Effect Sizes Hypothesized and Observed in Contemporary Phase III Trials of Targeted and Immunological Therapies for Advanced Cancer.

Authors:  Nicola Jane Lawrence; Felicia Roncolato; Andrew Martin; Robert John Simes; Martin R Stockler
Journal:  JNCI Cancer Spectr       Date:  2018-11-27

4.  Communicating treatment risks and benefits to cancer patients: a systematic review of communication methods.

Authors:  L F van de Water; J J van Kleef; W P M Dijksterhuis; I Henselmans; H G van den Boorn; N M Vaarzon Morel; K F Schut; J G Daams; E M A Smets; H W M van Laarhoven
Journal:  Qual Life Res       Date:  2020-04-24       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.